The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...
An experimental weight-loss pill helped people drop 13% of their body weight in a three-month period. The results from early ...
Novo Nordisk's experimental weight-loss pill, amycretin, demonstrated safety and tolerability in early-stage trials. The pill showed significant weight reduction, with patients losing up to 13.1% of ...
The first-in-human study has found that participants who received 50mg amycretin reduced their body weight by 10.4 per cent ...
Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...